Literature DB >> 4044032

Evolution of inflammatory response and cellular immune responses in a murine model of disseminated blastomycosis.

G S Deepe, C L Taylor, W E Bullock.   

Abstract

A reproducible model of disseminated blastomycosis was established in C57BL/6 mice by intravenous injection of 10(6) yeast-phase Blastomyces dermatiditis organisms. The infection progressed over 5 weeks to involve lungs, brains, superficial fascia, livers, and spleens of mice. By week 5, there was a greater number of organisms in lungs and brains than in livers and spleens. The tissue response in lungs, brains, and livers progressed from acute neutrophilic invasion before week 1 to pyogranuloma formation by week 5. Lymph nodes and spleens were remarkably spared. By week 5, infected mice became anergic to intradermal challenge with both specific Blastomyces antigen and a nonspecific antigen (sheep erythrocytes). At this time, the response to concanavalin A or phytohemagglutinin by splenocytes was markedly less than that of normal controls. Likewise, the plaque-forming cell response to sheep erythrocytes by splenocytes from infected mice was diminished. In coculture studies, splenocytes from 5-week-infected mice reduced the plaque-forming cell response by normal splenocytes. The development of this murine model should prove useful for elucidating the perturbations of immunoregulation associated with disseminated blastomycosis.

Entities:  

Mesh:

Year:  1985        PMID: 4044032      PMCID: PMC262154          DOI: 10.1128/iai.50.1.183-189.1985

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Blastomycosis. A review of 152 cases.

Authors:  J Schwarz; K Salfelder
Journal:  Curr Top Pathol       Date:  1977

2.  Histologic reactions to cell walls of an avirulent and a virulent strain of Blastomyces dermatitidis.

Authors:  R A Cox; L R Mills; G K Best; J F Denton
Journal:  J Infect Dis       Date:  1974-02       Impact factor: 5.226

3.  Further improvements in the plaque technique for detecting single antibody-forming cells.

Authors:  A J Cunningham; A Szenberg
Journal:  Immunology       Date:  1968-04       Impact factor: 7.397

4.  The immunological consequences of antigen overload in experimental mycobacterial infections of mice.

Authors:  G A Rook
Journal:  Clin Exp Immunol       Date:  1975-01       Impact factor: 4.330

5.  Perturbation of lymphocyte circulation in experimental murine leprosy. II. Nature of the defect.

Authors:  W E Bullock
Journal:  J Immunol       Date:  1976-10       Impact factor: 5.422

6.  Cellular immunity and nutrition in refractory disseminated blastomycosis.

Authors:  R B FitzSimons; A C Ferguson
Journal:  Can Med Assoc J       Date:  1978-08-26       Impact factor: 8.262

7.  Immunoregulatory responses in experimental disseminated histoplasmosis: lymphoid organ histopathology and serological studies.

Authors:  R P Artz; W E Bullock
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

8.  The spectrum of primary blastomycotic meningitis: a review of central nervous system blastomycosis.

Authors:  E F Gonyea
Journal:  Ann Neurol       Date:  1978-01       Impact factor: 10.422

9.  Mouse model of pulmonary blastomycosis: utility, simplicity, and quantitative parameters.

Authors:  R P Harvey; E S Schmid; C C Carrington; D A Stevens
Journal:  Am Rev Respir Dis       Date:  1978-04

10.  Immunization of dissociated spleen cell cultures from normal mice.

Authors:  R I Mishell; R W Dutton
Journal:  J Exp Med       Date:  1967-09-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Murine models of blastomycosis, coccidioidomycosis, and histoplasmosis.

Authors:  K N Sorensen; K V Clemons; D A Stevens
Journal:  Mycopathologia       Date:  1999       Impact factor: 2.574

2.  Fungal-strain-dependent alterations in the time course and mortality of chronic murine pulmonary blastomycosis.

Authors:  S A Moser; P J Koker; J E Williams
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.